SMC2

Across TCGA pan-cancer cohorts, SMC2 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated SMC2 data layer compared with 25 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher SMC2 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated SMC2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

UCEC, BLCA, and CESC are the cancer types where SMC2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	1.000	0.613	.001	32	view →
BLCA	DFS	Median	All	0.919	0.318	.006	29	view →
CESC	OS	Median	III,IV	0.068	0.756	<.001	12	view →
ESCA	DFS	Median	III,IV	0.080	0.442	<.001	6	view →
PRAD	DFS	Median	All	0.647	0.936	.007	6	view →
LUAD	DFS	Median	All	0.510	0.817	.018	1	view →
SKCM	DFS	Median	All	0.084	0.208	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

SMC2–UCEC (DFS)

Open the UCEC breakdown →